Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
C. Saltini (Rome, Italy). Immunotherapy (as an adjuvant therapeutic tool) of tuberculosis - does it have a future?. Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem

Member's Comments

No comment yet.

Related content which might interest you: Serial interferon-gamma release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations Year: 2013 The future of targeted therapies for sarcoidosis Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis Year: 2005 Tuberculosis therapy: past, present and future Source: Eur Respir J 2002; 20: 87S-94S Year: 2002 M. tuberculosis: immunology and vaccination Source: Eur Respir J 2001; 17: 537-557 Year: 2001 Interleukin 27 (IL27): A new tool for lung cancer gene immunotherapy? Source: Annual Congress 2012 - Special problems in thoracic surgery Year: 2012 Evaluate the potential of IP-10 as biomarker for the MDR-TB treatment outcome Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 New immunologic tools for the diagnosis and therapy of tuberculosis Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 Interleukin 27 (IL27) as a novel therapeutic tool in lung cancer immune therapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Omics and single molecule detection: the future of TB diagnostics Source: Eur Respir Mon 2012; 58: 144-153 Year: 2012 Initiation of anti-TNF therapy within 3 weeks of LTBI treatment in patients with immune-mediated inflammatory diseases Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014 A combinatorial dual-immunoassay predicts reactivation risk for patients with previously incomplete treatment for latent tuberculosis infection Source: International Congress 2016 – Active and latent tuberculosis: biomarkers Year: 2016 Therapeutic options for sarcoidosis: old and new Source: Annual Congress 2005 - PG15 - Therapeutic options for interstitial lung diseases in 2005 Year: 2005 LATE-BREAKING ABSTRACT: The performance of flow cytometry in the diagnosis of latent tuberculosis infection in patients under treatment with anti-TNFa and other biological agents Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations Year: 2013 Opportunist mycobacterial lung disease - which drug combination is more effective? Source: Breathe 2009; 6: 67-69 Year: 2009 Screening for tuberculosis in candidates for immunosuppressive therapy Source: Annual Congress 2009 - Clinical immunology of tuberculosis Year: 2009 Interferon-? liposome: a new system to improve drug delivery in the treatment of lung cancer Source: ERJ Open Res, 7 (3) 00555-2020; 10.1183/23120541.00555-2020 Year: 2021 Additional analysis of antigen-specific Interleukin-2 release does not improve the performance of IGRAs for the differentiation of different states of mycobacterium tuberculosis infection Source: International Congress 2014 – Future frontiers in the diagnosis of Mycobacterium tuberculosis infection Year: 2014 Interleukin-12 as successful adjuvant in tuberculosis treatment Source: Eur Respir J 2001; 17: 1049-1051 Year: 2001 Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients Source: Eur Respir J 2006; 28: 31-34 Year: 2006